JP2021155454A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021155454A5 JP2021155454A5 JP2021109883A JP2021109883A JP2021155454A5 JP 2021155454 A5 JP2021155454 A5 JP 2021155454A5 JP 2021109883 A JP2021109883 A JP 2021109883A JP 2021109883 A JP2021109883 A JP 2021109883A JP 2021155454 A5 JP2021155454 A5 JP 2021155454A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- erythrocytes
- target cell
- cell
- stimulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 24
- 210000003743 erythrocyte Anatomy 0.000 claims 17
- 238000000034 method Methods 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 208000023275 Autoimmune disease Diseases 0.000 claims 4
- 210000003850 cellular structure Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 206010053159 Organ failure Diseases 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000007912 intraperitoneal administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 238000007920 subcutaneous administration Methods 0.000 claims 2
- 239000006228 supernatant Substances 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- 108010081589 Becaplermin Proteins 0.000 claims 1
- 102100023995 Beta-nerve growth factor Human genes 0.000 claims 1
- 101710129634 Beta-nerve growth factor Proteins 0.000 claims 1
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims 1
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims 1
- 101710112538 C-C motif chemokine 27 Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 101710085500 C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 108010055166 Chemokine CCL5 Proteins 0.000 claims 1
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100023688 Eotaxin Human genes 0.000 claims 1
- 101710139422 Eotaxin Proteins 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims 1
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims 1
- -1 IFN-α2 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 101800003050 Interleukin-16 Proteins 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 108090000978 Interleukin-4 Proteins 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108010002586 Interleukin-7 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims 1
- 102000034655 MIF Human genes 0.000 claims 1
- 108060004872 MIF Proteins 0.000 claims 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 230000030833 cell death Effects 0.000 claims 1
- 230000011712 cell development Effects 0.000 claims 1
- 239000013592 cell lysate Substances 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000005754 cellular signaling Effects 0.000 claims 1
- 239000000470 constituent Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 210000003617 erythrocyte membrane Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000007913 intrathecal administration Methods 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000002437 synoviocyte Anatomy 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Claims (13)
- 標的細胞の活動を調節する方法であって:
a.) 赤血球を、該赤血球に関連する1以上のタンパク質のレベルを調節する少なくとも1つの薬剤と接触させることにより、刺激された赤血球を作製することであって、該少なくとも1つの薬剤が、タンパク質、プロテアーゼ阻害剤又は細胞である、前記作製すること;
b.) 該刺激された赤血球を該少なくとも1つの薬剤から分離すること;並びに
c.) 該標的細胞を:
(i) 該分離された刺激された赤血球;
(ii) 該分離された刺激された赤血球をインキュベートすること又は培養することから取得した上清;
(iii) 該分離された刺激された赤血球から取得した溶解物;
(iv) 該分離された刺激された赤血球から取得した膜;及び
(v) 該分離された刺激された赤血球から作製した赤血球ゴースト、からなる群から選択される、1以上の刺激された赤血球構成要素と混合すること、を含み、ここで該標的細胞を該1以上の分離された刺激された赤血球構成要素と混合することにより、該標的細胞の活動が調節される、前記方法。 - 前記刺激された赤血球により、細胞シグナル伝達、免疫反応、細胞発達、細胞成長、細胞死、細胞成長阻害、及び細胞修復からなる群から選択される、前記標的細胞の1以上の活動が調節される、請求項1記載の方法。
- 前記標的細胞が、免疫細胞、不死化細胞、癌細胞、幹細胞、内皮細胞、線維芽細胞、及び滑液細胞からなる群から選択されるものの1以上である、請求項2記載の方法。
- 前記標的細胞が対象由来である、請求項1記載の方法。
- 前記調節された標的細胞又は該調節された標的細胞由来の標的細胞構成要素が、対象への投与のためのものである、請求項1記載の方法。
- 前記対象への投与のための前記調節された標的細胞又は該調節された標的細胞由来の前記標的細胞構成要素の1以上が、標的細胞ゴースト、標的細胞膜、標的細胞溶解物、標的細胞画分、及び標的細胞をインキュベートすること又は培養することにより作製した上清からなる群から選択される、請求項5記載の方法。
- 前記調節された標的細胞又は該調節された標的細胞由来の前記標的細胞構成要素の1以上が、全身、局所、静脈内、皮下、関節内、筋肉内、くも膜下腔内、及び腹腔内からなる群から選択される1以上の経路による前記対象への投与のためのものである、請求項5記載の方法。
- 前記対象が、癌、感染症、臓器不全、自己免疫性疾患、自己免疫性障害、炎症、及び免疫不全からなる群から選択される疾患又は障害を有する、請求項5記載の方法。
- 請求項1に従って作製された、前記分離された刺激された赤血球、前記調節された標的細胞、及び/又は、該調節された標的細胞由来の前記標的細胞構成要素を含む、対象の疾患又は障害を予防、治療、又は改善するための医薬組成物であって、該疾患又は障害が、癌、感染症、臓器不全、自己免疫性疾患、自己免疫性障害、炎症、及び免疫不全からなる群から選択される、前記医薬組成物。
- 前記分離された刺激された赤血球、前記調節された標的細胞、及び/又は、該調節された標的細胞由来の前記標的細胞構成要素が、全身、局所、静脈内、皮下、関節内、筋肉内、くも膜下腔内、及び腹腔内からなる群から選択される1以上の経路によって前記対象に投与されるように用いられることを特徴とする、請求項9記載の医薬組成物。
- 前記赤血球に関連する1以上のタンパク質が、サイトカイン、ケモカイン、又は成長因子である、請求項1記載の方法。
- 前記赤血球に関連する1以上のタンパク質が、塩基性FGF、エオタキシン、G-CSF、GM-CSF、IFN-γ、IL-1β、ILlra、IL-2、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-12(p70)、IL-13、IL-15、IL-17、IP-10、MCP-1、MIP-lα、MIP-lβ、PDGF-BB、RANTES、TNF-α、及びVEGFからなる群から選択される、請求項1記載の方法。
- 前記赤血球に関連する1以上のタンパク質が、IL-la、IL-2Ra、IL-3、IL-12、IL-16、IL-18、CTACK、GRO-α、HGF、IFN-α2、LIF、MCP-3、M-CSF、MIF、MIG、β-NGF、SCF、SCGF-β、SDF-lα、TNF-β、及びTRAILからなる群から選択される、請求項1記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2015905309A AU2015905309A0 (en) | 2015-12-22 | Therapeutic methods using erythrocytes | |
AU2015905309 | 2015-12-22 | ||
JP2018532777A JP2018538343A (ja) | 2015-12-22 | 2016-12-22 | 赤血球を用いる治療方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532777A Division JP2018538343A (ja) | 2015-12-22 | 2016-12-22 | 赤血球を用いる治療方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021155454A JP2021155454A (ja) | 2021-10-07 |
JP2021155454A5 true JP2021155454A5 (ja) | 2022-04-26 |
Family
ID=59088638
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532777A Pending JP2018538343A (ja) | 2015-12-22 | 2016-12-22 | 赤血球を用いる治療方法 |
JP2021109883A Pending JP2021155454A (ja) | 2015-12-22 | 2021-07-01 | 赤血球を用いる治療方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018532777A Pending JP2018538343A (ja) | 2015-12-22 | 2016-12-22 | 赤血球を用いる治療方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11564948B2 (ja) |
EP (1) | EP3393482A4 (ja) |
JP (2) | JP2018538343A (ja) |
KR (1) | KR20180102096A (ja) |
CN (1) | CN108883133A (ja) |
AU (1) | AU2016374643B2 (ja) |
CA (1) | CA3009369A1 (ja) |
SG (1) | SG11201805052YA (ja) |
WO (1) | WO2017106899A2 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013059343A1 (en) | 2011-10-17 | 2013-04-25 | Massachusetts Institute Of Technology | Intracellular delivery |
SG10201801188XA (en) | 2013-08-16 | 2018-03-28 | Massachusetts Inst Technology | Selective delivery of material to cells |
US11111472B2 (en) | 2014-10-31 | 2021-09-07 | Massachusetts Institute Of Technology | Delivery of biomolecules to immune cells |
EP3218492A4 (en) | 2014-11-14 | 2018-10-10 | Massachusetts Institute Of Technology | Disruption and field enabled delivery of compounds and compositions into cells |
CA2971626A1 (en) | 2015-01-12 | 2016-07-21 | Massachusetts Institute Of Technology | Gene editing through microfluidic delivery |
EP4257675A3 (en) | 2015-07-09 | 2024-01-03 | Massachusetts Institute of Technology | Delivery of materials to anucleate cells |
WO2017041051A1 (en) | 2015-09-04 | 2017-03-09 | Sqz Biotechnologies Company | Intracellular delivery of biomolecules to cells comprising a cell wall |
CN108700565B (zh) | 2015-10-07 | 2021-10-29 | 善威生物私人有限公司 | 血液制备和图谱分析 |
US11693006B2 (en) | 2016-12-20 | 2023-07-04 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
WO2022192429A1 (en) * | 2021-03-10 | 2022-09-15 | Terasaki Insutitute For Biomedical Innovation | Constructs comprising fibrin or other blood products for meat cultivation and other applications |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4931276A (en) | 1987-10-30 | 1990-06-05 | Franco Robert S | Method for introducing desired agents into red blood cells |
US5858358A (en) * | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
AU8869291A (en) * | 1990-10-04 | 1992-04-28 | University Of Virginia Alumni Patents Foundation, The | Primate erythrocyte bound monoclonal antibody heteropolymers |
FR2778851B1 (fr) * | 1998-05-19 | 2002-07-26 | Aetsrn | Composition a base d'inhibiteurs de cysteine-proteases pour retarder la senescence, l'autodestruction et l'hemolyse des erythrocytes |
US8431117B2 (en) * | 1999-08-30 | 2013-04-30 | David S Terman | Sickled erythrocytes with anti-tumor agents induce tumor vaso-occlusion and tumoricidal effects |
MXPA03000765A (es) * | 2000-07-24 | 2004-05-21 | Gendel Ltd | Suministro de polipeptido il-2. |
ES2498369T3 (es) | 2002-04-16 | 2014-09-24 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. | Un marcador para medir cirrosis hepática |
GB0325483D0 (en) | 2003-10-31 | 2003-12-03 | Plasmacute As | Assay |
US20080095749A1 (en) * | 2004-03-22 | 2008-04-24 | Sudeepta Aggarwal | Mesenchymal stem cells and uses therefor |
US7378054B2 (en) | 2004-04-16 | 2008-05-27 | Savvipharm Inc | Specimen collecting, processing and analytical assembly |
US20060166223A1 (en) | 2005-01-26 | 2006-07-27 | Reed Michael W | DNA purification and analysis on nanoengineered surfaces |
EP1875248A2 (en) | 2005-03-29 | 2008-01-09 | Inverness Medical Switzerland GmbH | Device and method of monitoring a patient |
WO2008134526A2 (en) | 2007-04-27 | 2008-11-06 | University Of Florida Research Foundation Inc. | Glycoprotein profiling of bladder cancer |
FR2919804B1 (fr) * | 2007-08-08 | 2010-08-27 | Erytech Pharma | Composition et vaccin therapeutique anti-tumoral |
CN102037355A (zh) | 2008-03-04 | 2011-04-27 | 里奇诊断学股份有限公司 | 基于多重生物标记物板块诊断和监测抑郁症 |
EP3282010A1 (en) | 2008-05-06 | 2018-02-14 | Astellas Institute for Regenerative Medicine | Methods for producing enucleated erythroid cells derived from pluripotent stem cells |
EP2442641A4 (en) * | 2009-06-16 | 2016-03-09 | Univ Columbia | METHOD FOR REDUCING SIDE EFFECTS OF THE TRANSFUSION OF AGED RED BLOOD CELLS |
WO2011018288A1 (en) | 2009-08-13 | 2011-02-17 | Basf Se | Means and methods for diagnosingthyroid disorders |
WO2011091154A2 (en) * | 2010-01-21 | 2011-07-28 | The Regents Of The University Of California | Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
WO2011127056A2 (en) | 2010-04-05 | 2011-10-13 | The Uab Research Foundation | Biomarkers for assessing exposure to ionizing radiation and absorbed dose |
US20150111238A1 (en) | 2011-05-31 | 2015-04-23 | Singapore Health Services Pte. Ltd. | Method for detecting disease biomarkers |
CA2839106C (en) * | 2011-07-06 | 2018-01-02 | Histocell S.L. | A treatment method for mesenchymal stem cells and their application as a treatment of oxidative stress related diseases |
GB201116767D0 (en) * | 2011-09-28 | 2011-11-09 | St George S Hospital Medical School | Treatment for mitrochondrial neurogastrointestinal encephalomyopathy |
AU2013237419B2 (en) | 2012-03-21 | 2016-04-28 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (AML) |
HU230341B1 (hu) * | 2012-04-20 | 2016-02-29 | Advancell Diagnosztika Kft. | A vörösvérsejt-membrán kvantitatív biomarkerei |
JP6329537B2 (ja) * | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス, インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
KR102223080B1 (ko) * | 2013-05-10 | 2021-03-04 | 애리델 에스.피.에이. | 하나 이상의 약제학적 관심 물질이 로딩된 적혈구를 제조하는 방법 및 이렇게 하여 수득된 적혈구 |
JP6383920B2 (ja) | 2013-09-11 | 2018-09-05 | 有限会社ピコデバイス | パーキンソン病の判定基準とする方法 |
WO2015156586A1 (ko) * | 2014-04-07 | 2015-10-15 | 한양대학교 산학협력단 | 적혈구계 세포의 인 비트로 확장 |
CN107735095B (zh) * | 2015-05-18 | 2022-06-14 | 希玛奈克斯特股份有限公司 | 储存全血的方法及其组合物 |
CN108700565B (zh) | 2015-10-07 | 2021-10-29 | 善威生物私人有限公司 | 血液制备和图谱分析 |
US11693006B2 (en) | 2016-12-20 | 2023-07-04 | Sangui Bio Pty. Ltd | Blood profiling with protease inhibitors |
-
2016
- 2016-12-22 JP JP2018532777A patent/JP2018538343A/ja active Pending
- 2016-12-22 US US16/064,973 patent/US11564948B2/en active Active
- 2016-12-22 WO PCT/AU2016/000404 patent/WO2017106899A2/en active Application Filing
- 2016-12-22 EP EP16876988.3A patent/EP3393482A4/en active Pending
- 2016-12-22 KR KR1020187020347A patent/KR20180102096A/ko not_active Application Discontinuation
- 2016-12-22 CA CA3009369A patent/CA3009369A1/en active Pending
- 2016-12-22 CN CN201680082308.2A patent/CN108883133A/zh active Pending
- 2016-12-22 SG SG11201805052YA patent/SG11201805052YA/en unknown
- 2016-12-22 AU AU2016374643A patent/AU2016374643B2/en active Active
-
2021
- 2021-07-01 JP JP2021109883A patent/JP2021155454A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2021155454A5 (ja) | ||
Rose-John et al. | The role of IL-6 in host defence against infections: immunobiology and clinical implications | |
Himmerich et al. | Cytokine research in depression: principles, challenges, and open questions | |
Cobleigh et al. | Protective and pathological properties of IL-22 in liver disease: implications for viral hepatitis | |
Sawa et al. | RORγt+ innate lymphoid cells regulate intestinal homeostasis by integrating negative signals from the symbiotic microbiota | |
Vatrella et al. | Dupilumab: a novel treatment for asthma | |
Withers et al. | Transient inhibition of ROR-γt therapeutically limits intestinal inflammation by reducing TH17 cells and preserving group 3 innate lymphoid cells | |
Kimura et al. | Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice | |
Rose et al. | Murine lung eosinophil activation and chemokine production in allergic airway inflammation | |
Hammerich et al. | Role of IL‐17 and Th17 cells in liver diseases | |
Browne et al. | Anticytokine autoantibodies in infectious diseases: pathogenesis and mechanisms | |
Moro et al. | Innate production of TH2 cytokines by adipose tissue-associated c-Kit+ Sca-1+ lymphoid cells | |
Yoshimoto et al. | Basophils contribute to TH2-IgE responses in vivo via IL-4 production and presentation of peptide–MHC class II complexes to CD4+ T cells | |
Khanam et al. | Altered frequencies of dendritic cells and IFN‐γ‐secreting T cells with granulocyte colony‐stimulating factor (G‐CSF) therapy in acute‐on‐chronic liver failure | |
Ozasa et al. | Cyclic GMP-AMP triggers asthma in an IL-33-dependent manner that is blocked by amlexanox, a TBK1 inhibitor | |
Gimeno Brias et al. | The role of IL-22 in viral infections: paradigms and paradoxes | |
Harvey et al. | The transcriptomic response of rat hepatic stellate cells to endotoxin: implications for hepatic inflammation and immune regulation | |
JP2018538343A5 (ja) | ||
Lindahl et al. | Interleukin-22 influences the Th1/Th17 axis | |
Giri et al. | Immune status of patients with inherited bone marrow failure syndromes | |
Baxter et al. | Interferon gamma modulation of disease manifestation and the local antibody response to alphavirus encephalomyelitis | |
Choi et al. | Macrophage‐derived progranulin promotes allergen‐induced airway inflammation | |
Hu et al. | Interleukin-1β-induced IRAK1 ubiquitination is required for TH-GM-CSF cell differentiation in T cell-mediated inflammation | |
Zhu et al. | Small proline-rich protein 3 regulates IL-33/ILC2 axis to promote allergic airway inflammation | |
Uller et al. | Viral induced overproduction of epithelial TSLP: role in exacerbations of asthma and COPD? |